Stock VINC VINCERX PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Vincerx Pharma, Inc. Stock

Equities

VINC

US92731L1061

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.9 USD -5.28% Intraday chart for Vincerx Pharma, Inc. -10.00% -23.73%
Apr. 09 Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT
Apr. 09 Top Premarket Decliners MT

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 19.27M
Net income 2024 * -24M Net income 2025 * -32M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.88 x
P/E ratio 2025 *
-1.02 x
Employees 42
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75%
More Fundamentals * Assessed data

Chart Vincerx Pharma, Inc.

Dynamic Chart

Latest news about Vincerx Pharma, Inc.

Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT
Top Premarket Decliners MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell MT
Vincerx Pharma, Inc. Presents Positive Preliminary Phase 1 Data for Vip236 and Updates on Pipeline Progress At the American Association for Cancer Research Annual Meeting 2024 CI
Vincerx Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Tech in Focus on -2- DJ
Vincerx Pharma Shares Jump After Results of Blood Cancer Treatment Trial MT
Top Premarket Gainers MT
Vincerx Pharma, Inc. Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma CI
Vincerx Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Vincerx Pharma Doses First Patient in Early-Stage Trial of Blood Cancer Drug Candidate MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Vincerx Pharma Says US FDA Approved Phase 1 Trial for Potential Acute Myeloid Leukemia Treatment MT
More news

Analyst Recommendations on Vincerx Pharma, Inc.

Chardan Trims Price Target on Vincerx Pharma to $3 From $4, Keeps Buy Rating MT
SVB Securities Adjusts Vincerx Pharma's Price Target to $5 From $6, Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Vincerx Pharma's Price Target to $8 From $22, Reiterates Overweight Rating MT
Chardan Cuts Price Target on Vincerx Pharma to $4 From $11 as it Shifts VIP152 Launch to 2026 From 2024 Reiterates Buy Rating MT
SVB Securities Adjusts Vincerx Pharma's Price Target to $6 From $19, Keeps Outperform Rating MT
More recommendations

Press releases Vincerx Pharma, Inc.

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024  AQ
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 AQ
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update AQ
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 AQ
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma AQ
More press releases

Quotes and Performance

1 day-5.28%
1 week-10.00%
Current month-82.21%
1 month-81.67%
3 months-21.74%
6 months-14.29%
Current year-23.73%
More quotes

Highs and lows

1 week
0.75
Extreme 0.75
0.98
1 month
0.75
Extreme 0.75
7.59
Current year
0.75
Extreme 0.75
9.37
1 year
0.61
Extreme 0.61
9.37
3 years
0.61
Extreme 0.61
18.43
5 years
0.61
Extreme 0.61
26.75
10 years
0.61
Extreme 0.61
26.75
More quotes

Managers and Directors - Vincerx Pharma, Inc.

Managers TitleAgeSince
Soo In Hwang FOU
 Founder 64 18-12-18
Raquel Izumi FOU
 Founder 54 18-12-18
Tom Thomas FOU
 Founder 64 18-12-18
Members of the board TitleAgeSince
Ahmed Hamdy CEO
 Chief Executive Officer 59 18-12-18
Laura Bushnell BRD
 Director/Board Member 56 20-12-22
Brian Druker BRD
 Director/Board Member 68 20-12-22
More insiders

Quotes

Date Price Change Volume
24-04-18 0.9 -5.28% 531,361
24-04-17 0.9502 +1.12% 358,138
24-04-16 0.9397 +8.01% 911,198
24-04-15 0.87 -11.22% 1,265,618
24-04-12 0.98 -2.00% 913,245

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes

Company Profile

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9 USD
Average target price
9 USD
Spread / Average Target
+900.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VINCERX PHARMA, INC. Stock Vincerx Pharma, Inc.
-23.73% 20.35M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VINC Stock